Topic:

R&D

Latest Headlines

Latest Headlines

Novavax reports positive top-line data from PhII trial of RSV vaccine

There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.

AbbVie, Roche score a pivotal success with their 'breakthrough' cancer drug

A new oncology compound from AbbVie and Roche's Genentech division cleared its primary hurdle in a Phase II blood cancer trial, opening the door to an FDA filing by year's end.

Helius enters clinical trial of its PoNS brain stimulation device to treat traumatic brain injury

Helius Medical Technologies is set to begin a Phase III clinical trial with the U.S. Army Medical Research and Materiel Command for its Portable Neuromodulation Stimulator (PoNS), which is designed to treat balance disorder for patients with traumatic brain injury.

UPDATED: Nearing the brink, Eleven Bio bets on another PhIII eye study and shares soar

Less than three months after seeing its share price get crushed in the panic following a late-stage failure of its lead drug, Cambridge, MA-based Eleven Biotherapeutics is rolling the dice in a last-ditch effort to produce approval-worthy Phase III data.

Biocept partners with UC Irvine on liquid biopsy research

Liquid biopsy player Biocept is teaming up with the University of California, Irvine, to evaluate blood-based biomarkers (as opposed to tissue-based ones) in patients with metastatic cancers. The duo hopes to validate liquid biopsies as a treatment guide for precision medicines and develop a system for monitoring tumor mutations to identify signs of resistance to therapy.

What does Google's corporate shuffle mean for its biotech ambitions?

Google is divvying up its composite parts, becoming, depending on whom you ask, the new Berkshire Hathaway, the next General Electric or something heretofore never seen. But the move could have mixed implications for Google's nascent but growing life sciences empire.

Clovis pairs up with Roche on a high-profile immuno-oncology project

Clovis Oncology is planning to test whether its oral lung cancer drug can work in tandem with a closely watched injectable treatment from Roche's Genentech division, hoping to expand the potential for its breakthrough-designated therapy.

Liposomal drug delivery enters the spotlight in new Russian-U.S. report

Scientists have long been looking to liposomes for drug delivery, and a new contingent of researchers from Moscow and Boston published a report this week in the journal Chemical Review looking back at how far the tiny vehicles have come since their development in the 1960s and forward to where they have yet to go.

Adynxx eyes an IPO, late-stage program after pain drug clears a PhII hurdle

Adynxx says that their second shot at statistically significant results in a midstage study for their lead pain drug proved the charm. The San Francisco-based biotech didn't post any data, but CEO Rick Orr said that the drug hit the primary endpoint without raising any red flags on the safety side.

VisionGate sets sights on FDA approval for noninvasive lung cancer Dx

As lung cancer diagnostics pick up steam in the industry, Phoenix, AZ-based VisionGate is looking to distinguish itself from the pack with its noninvasive test for the disease. And the company is counting on FDA approval for its innovative technology to take business to the next level.